Loading clinical trials...
Loading clinical trials...
A Phase I/II, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy
Conditions
Interventions
MIL116
Matching Placebo
Locations
1
China
Peking University First Hospital
Beijing, China
Start Date
February 5, 2026
Primary Completion Date
June 1, 2028
Completion Date
June 1, 2029
Last Updated
April 13, 2026
NCT06291376
NCT06466135
NCT05248646
NCT05852938
NCT04663204
NCT04573478
Lead Sponsor
Beijing Mabworks Biotech Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions